Adjuvant Anti-Recurrence Treatment With Rapamycin on Early-stage HCC

• Status: Completed
• Trial end date: 2015-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the clinical effect of rapamycin combined with TACE on early-stage HCC with overexpression of ASPH after radical surgery using randomized controlled study and provide a new anti-recurrence treatment for HCC patients after operation.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eastern Hepatobiliary Surgery Hospital
• Treatments: Everolimus; Sirolimus

Criteria

Inclusion Criteria:

1. Via clinical diagnosis and confirm it is primary liver cancer

2. Pathological evidence of HCC

3. Estimate tumor can gain treatment of curing operation

4. No evidence for extrahepatic metestasis

5. liver function ：Child-Pugh A/B

6. BCLC stage：0/1；TNM stage：Ⅰ

Exclusion Criteria:

1. reject to attend；

2. impossible to come to our hospital for physical examination regularly.

3. cancer epitome、seed focus、lymph node or distant metastasis

4. Blood clotting function hindrance; 5, Patients with other diseases which may affect the treatment mentioned.